United Therapeutics Corporation Depreciation
United Therapeutics Corporation (UTHR) reported Depreciation of $44.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- United Therapeutics Corporation depreciation for the quarter ending 2026-06-30 was $22.80M, a 9.09% increase year-over-year.
- United Therapeutics Corporation depreciation for the quarter ending 2026-03-31 was $21.60M, a 10.20% increase year-over-year.
- United Therapeutics Corporation depreciation for the quarter ending 2025-12-31 was $22.70M, a 17.01% increase year-over-year.
- United Therapeutics Corporation depreciation for the quarter ending 2025-09-30 was $21.50M, a 14.36% increase year-over-year.
- United Therapeutics Corporation depreciation for fiscal 2025 was $84.70M, a 18.30% increase from fiscal 2024.
- United Therapeutics Corporation depreciation for fiscal 2024 was $71.60M, a 35.35% increase from fiscal 2023.
- United Therapeutics Corporation depreciation for fiscal 2023 was $52.90M, a 3.32% increase from fiscal 2022.
- United Therapeutics Corporation depreciation for fiscal 2022 was $51.20M, a 2.81% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $44.40M 10-Q · filed 2026-08-05 | $67.10M derived: sum of 3 quarters · filed 2026-08-05 | $88.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $21.60M 10-Q · filed 2026-05-06 | $44.30M derived: sum of 2 quarters · filed 2026-05-06 | $65.80M derived: sum of 3 quarters · filed 2026-05-06 | $86.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $22.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $44.20M derived: sum of 2 quarters · filed 2026-02-25 | $65.10M derived: sum of 3 quarters · filed 2026-08-05 | $84.70M 10-K · filed 2026-02-25 |
| 2025-09-30 | $21.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $42.40M derived: sum of 2 quarters · filed 2026-08-05 | $62.00M 10-Q · filed 2025-10-29 | $81.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $20.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $40.50M 10-Q · filed 2026-08-05 | $59.90M derived: sum of 3 quarters · filed 2026-08-05 | $78.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $19.60M 10-Q · filed 2026-05-06 | $39.00M derived: sum of 2 quarters · filed 2026-05-06 | $57.80M derived: sum of 3 quarters · filed 2026-05-06 | $76.40M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $19.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $38.20M derived: sum of 2 quarters · filed 2026-02-25 | $56.80M derived: sum of 3 quarters · filed 2026-02-25 | $71.60M 10-K · filed 2026-02-25 |
| 2024-09-30 | $18.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $37.40M derived: sum of 2 quarters · filed 2025-10-29 | $52.20M 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $18.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $33.40M 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | $14.80M 10-Q · filed 2025-04-30 | |||
| 2023-12-31 | $52.90M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $51.20M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $49.80M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $49.70M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $45.70M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $35.80M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $30.50M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $31.00M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $31.80M 10-K · filed 2018-02-21 | |||
| 2014-12-31 | $30.80M 10-K · filed 2017-02-22 | |||
| 2013-12-31 | $28.60M 10-K · filed 2016-02-25 | |||
| 2012-12-31 | $25.00M 10-K · filed 2015-02-24 | |||
| 2011-12-31 | $18.20M 10-K · filed 2014-02-25 | |||
| 2010-12-31 | $17.60M 10-K · filed 2013-02-26 | |||
| 2009-12-31 | $10.70M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |